levofloxacin / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   137 Trials   137 Trials   5343 News 


«12...2021222324252627282930...9091»
  • ||||||||||  Enrollment change, Trial termination:  InDEX: The Individualized M(X) Drug-resistant TB Treatment Strategy Study (clinicaltrials.gov) -  Sep 1, 2023   
    P4,  N=205, Terminated, 
    N=448 --> 205 | Recruiting --> Terminated; WHO 2022 guidelines for DR-TB treatment are set to change. These guidelines recommend the use of an all-oral short course BPAL regimen.Therefore ongoing implementation of the study is considered futile.
  • ||||||||||  Arcanobacterium Haemolyticum - Infection in an Immunocompetent Child (e-Poster Hall) -  Aug 30, 2023 - Abstract #EADV2023EADV_2999;    
    The pathogenesis and treatment of this disease are still unclear. A clinical diagnosis of bullous tinea pedis had been made by his primary care physician and he had been commenced on topical clotrimazole, hydrocortisone and mupirocin...Whilst treatment protocol for the management of A. haemolyticum soft tissue infection hasn
  • ||||||||||  Zeftera (ceftobiprole) / Basilea
    Preclinical, Journal:  Ceftobiprole Medocaril Is an Effective Post-Exposure Treatment in the Fischer 344 Rat Model of Pneumonic Tularemia. (Pubmed Central) -  Aug 26, 2023   
    Furthermore, no evidence of infection was detected in any rat that completed ceftobiprole medocaril or levofloxacin treatment and survived to the end of the post-treatment observation period. Overall, survival rates, body weights, and bacterial burdens consistently demonstrated that treatment with ceftobiprole medocaril is efficacious against otherwise fatal cases of pneumonic tularemia in the rat model.
  • ||||||||||  Baxdela (delafloxacin) / Menarini, Melinta Therap
    Review, Journal:  Updated Review on Clinically-Relevant Properties of Delafloxacin. (Pubmed Central) -  Aug 26, 2023   
    During phases II and III clinical trials, delafloxacin showed non-inferiority compared to standard-of-care therapy in the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia, which resulted in its approval in 2017 by the Food and Drug Administration for indications. Thanks to its overall good tolerance, its broad-spectrum in vitro activity, and its ease of use, it could represent a promising molecule for the treatment of bacterial infections.
  • ||||||||||  Journal:  Multi-drug resistance pattern of bacterial isolates from urinary tract infection. (Pubmed Central) -  Aug 25, 2023   
    Trimethoprim sulfamethazine (26.8%), penicillin (0%), cefepime (27.8%), cefotaxime (23.7%), aztreonam (2.1%), meropenem (86.6%), ciprofloxacin (51.5%), amoxicillin/clavulanic acid (37.1%), nitrofurantoin (70.1%), gentamycin (73%), ceftazidime (19.5%), levofloxacin (51.5%) and ceftriaxone (25.77%) were subjected to antibiotic susceptibility testing. It is concerning that among the 13 antibiotics examined, solely nitrofurantoin displayed oral efficacy as an effective treatment choice for UTIs.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Preclinical, Journal, Combination therapy:  Looking for Stenotrophomonas maltophilia treatment: in (Pubmed Central) -  Aug 24, 2023   
    Trimethoprim-sulfamethoxazole (SXT) is the treatment of choice but the increase of resistant strains or adverse drug reactions limited its clinical use...Susceptibility of SXT and levofloxacin (LEV) was also investigated...CZA in combination with ATM demonstrated synergistic activity against 86% of the strains, including all those resistant to CZA. The combination of CZA with ATM provides a new therapeutic option for the treatment of severe respiratory infections in critically ill patients.
  • ||||||||||  Trial completion, Trial completion date:  endTB: Evaluating Newly Approved Drugs for Multidrug-resistant TB (clinicaltrials.gov) -  Aug 23, 2023   
    P3,  N=754, Completed, 
    Improvements in high-throughput nucleotide sequencing are required to reduce misdiagnosis rates. Active, not recruiting --> Completed | Trial completion date: Sep 2023 --> Jun 2023
  • ||||||||||  levofloxacin / Generic mfg., moxifloxacin ophthalmic / Generic mfg.
    Trial completion, Surgery:  Safety Profile Comparison of Undiluted Intracameral Moxifloxacin vs. Levofloxacin in Cataract Surgery (clinicaltrials.gov) -  Aug 22, 2023   
    P1,  N=68, Completed, 
    In conclusion, TCZ?+?GEM/nab-PTX-rechallenge had a manageable safety profile and showed preliminary activity via inhibition of CAF and improved intratumoral drug infiltration in MPC. Recruiting --> Completed
  • ||||||||||  Biomarker, Journal:  A comprehensive study of Helicobacter pylori infection: molecular analysis, antibacterial susceptibility, and histopathological examination. (Pubmed Central) -  Aug 21, 2023   
    The resistance rates for metronidazole, clarithromycin, levofloxacin, and rifampicin were 67.2%, 27.9%, 34.4% and 13.11%, respectively...It was observed significant genotypic heterogeneity and virulence gene diversity within the isolates. A considerable resistance rate detected against antibiotics such as clarithromycin, metronidazole, and levofloxacin, which are frequently used in the eradication of H. pylori, should be taken into consideration when creating regional empirical treatment regimens.
  • ||||||||||  Journal:  Treating necrotizing fasciitis patients at the topmost referral hospital in West Java, Indonesia: 6?years experience. (Pubmed Central) -  Aug 19, 2023   
    We conclude that the most found bacterial aetiology was Acinetobacter baumanii though it has no significant relation to mortality. We highly recommend early aggressive surgical intervention in reducing mortality rate due to necrotizing fasciitis for source control accompanied by deliberate defect closure and early administration of empirical antibiotics with more susceptibility for gram-negative bacteria, such as Meropenem.
  • ||||||||||  levofloxacin / Generic mfg., clarithromycin / Generic mfg.
    Journal, Polymerase Chain Reaction:  Quantitative Polymerase Chain Reaction (qPCR)-Based Rapid Diagnosis of Helicobacter pylori Infection and Antibiotic Resistance. (Pubmed Central) -  Aug 18, 2023   
    Specifically, we used qPCR to detect rea for H. pylori infection and mutations in the 23S rRNA and gyrA genes, which encode resistance against clarithromycin and levofloxacin, respectively. Compared to routinely used culturing techniques, this protocol provides a noninvasive, low-cost, and time-saving technique to detect H. pylori infection and determine its antibiotic resistance using qPCR.